HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Comparative study of the antiarrhythmic activity of mu- and delta-opioid receptor agonists during acute cardiac ischemia and reperfusion models in rats].

Abstract
It has been established that pretreatment with the selective mu-opioid receptor (OR) agonist DALDA (0.1 mg/kg, i.v.) or the selective delta1-OR agonists DPDPE (0.09 mg/kg) and/or (-)-TAN-67 (0.08 mg/kg) has no effect on the incidence of ventricular arrhythmias induced by a 10-min coronary artery occlusion and a 10-min reperfusion in ketamine-anesthetized rats. In contrast, the pretreatment with the selective delta2-OR agonist deltorphin II (0.12 mg/kg) and the proposed delta2-OR agonists deltorphin D (0.3 mg/kg) and/or dermorphin H (0.23 mg/kg) increases cardiac resistance to the arrhythmogenic action of acute ischemia and reperfusion. Administration of the mixed mu- and delta-OR agonist dalargin (0.12 mg/kg) 15 min before the coronary artery ligation abolished only the reperfusive ventricular fibrillation. It is concluded that peptidergic stimulation of delta2-ORs can be used as a new means of increasing cardiac tolerance to the arrhythmogenic effects of acute ischemia and reperfusion.
AuthorsN V Solenkova, L N Maslov, E V Budankova, A Iu Lishmanov, P Oeltgen, M Govindaswami, Zh D Bespalova, M V Ovchinnikov, H Nagaze
JournalEksperimental'naia i klinicheskaia farmakologiia (Eksp Klin Farmakol) 2005 Nov-Dec Vol. 68 Issue 6 Pg. 25-9 ISSN: 0869-2092 [Print] Russia (Federation)
PMID16405030 (Publication Type: Comparative Study, English Abstract, Journal Article)
Chemical References
  • Anti-Arrhythmia Agents
  • Receptors, Opioid, delta
  • Receptors, Opioid, mu
Topics
  • Animals
  • Anti-Arrhythmia Agents (pharmacology)
  • Male
  • Myocardial Reperfusion Injury (complications, metabolism, prevention & control)
  • Organ Culture Techniques
  • Rats
  • Rats, Wistar
  • Receptors, Opioid, delta (agonists)
  • Receptors, Opioid, mu (agonists)
  • Ventricular Fibrillation (etiology, prevention & control)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: